View Item 

Show simple item record

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial
dc.contributor.authorGoldkorn, Amiren_US
dc.contributor.authorEly, Benjaminen_US
dc.contributor.authorTangen, Catherine M.en_US
dc.contributor.authorTai, Yu‐chongen_US
dc.contributor.authorXu, Tongen_US
dc.contributor.authorLi, Honglien_US
dc.contributor.authorTwardowski, Przemyslawen_US
dc.contributor.authorVeldhuizen, Peter J. Vanen_US
dc.contributor.authorAgarwal, Neerajen_US
dc.contributor.authorCarducci, Michael A.en_US
dc.contributor.authorMonk, J. Paulen_US
dc.contributor.authorGarzotto, Marken_US
dc.contributor.authorMack, Philip C.en_US
dc.contributor.authorLara, Primoen_US
dc.contributor.authorHigano, Celestia S.en_US
dc.contributor.authorHussain, Mahaen_US
dc.contributor.authorVogelzang, Nicholas J.en_US
dc.contributor.authorThompson, Ian M.en_US
dc.contributor.authorCote, Richard J.en_US
dc.contributor.authorQuinn, David I.en_US
dc.date.accessioned2015-03-05T18:24:42Z
dc.date.available2016-05-10T20:26:28Zen
dc.date.issued2015-04-15en_US
dc.identifier.citationGoldkorn, Amir; Ely, Benjamin; Tangen, Catherine M.; Tai, Yu‐chong ; Xu, Tong; Li, Hongli; Twardowski, Przemyslaw; Veldhuizen, Peter J. Van; Agarwal, Neeraj; Carducci, Michael A.; Monk, J. Paul; Garzotto, Mark; Mack, Philip C.; Lara, Primo; Higano, Celestia S.; Hussain, Maha; Vogelzang, Nicholas J.; Thompson, Ian M.; Cote, Richard J.; Quinn, David I. (2015). "Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial." International Journal of Cancer 136(8): 1856-1862.en_US
dc.identifier.issn0020-7136en_US
dc.identifier.issn1097-0215en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/110753
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherCold Spring Harbor Laboratory Pressen_US
dc.subject.otherprognosisen_US
dc.subject.otherbiomarkeren_US
dc.subject.otherprostate canceren_US
dc.subject.othercirculating tumor cellsen_US
dc.subject.othertelomerase activityen_US
dc.titleCirculating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trialen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/110753/1/ijc29212.pdf
dc.identifier.doi10.1002/ijc.29212en_US
dc.identifier.sourceInternational Journal of Canceren_US
dc.identifier.citedreferenceFizazi KS, Higano CS, Nelson JB, et al. Phase III, randomized, placebo‐controlled study of docetaxel in combination with zibotentan in patients with metastatic castration‐resistant prostate cancer. J Clin Oncol 2013; 31: 1740 – 48.en_US
dc.identifier.citedreferenceSiegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11 – 30.en_US
dc.identifier.citedreferenceShaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castration‐resistant prostate cancer. Clin Cancer Res 2007; 13: 2023 – 29.en_US
dc.identifier.citedreferenceDanila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011; 17: 3903 – 12.en_US
dc.identifier.citedreferenceMakarov DV, Loeb S, Getzenberg RG, et al. Biomarkers for prostate cancer. Annu Rev Med 2009; 60: 139 – 51.en_US
dc.identifier.citedreferenceKelly WK, Halabi S, Carducci M, et al. Randomized, double‐blind, placebo‐controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration‐resistant prostate cancer: CALGB 90401. J Clin Oncol 2012; 30: 1534 – 40.en_US
dc.identifier.citedreferenceGlass TR, Tangen CM, Crawford ED, et al. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003; 169: 164 – 9.en_US
dc.identifier.citedreferenceXu T, Xu Y, Liao CP, et al. Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo. Mol Cancer Therap 2010; 9: 438 – 49.en_US
dc.identifier.citedreferenceGoldkorn A, Blackburn EH. Assembly of mutant template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res 2006; 66: 5763 – 71.en_US
dc.identifier.citedreferenceLara PM, Jr, Ely B, Quinn DI, et al. Serum biomarkers of bone metabolism in castration resistant prostate cancer patients with skeletal metastases. J Natl Cancer Inst 2014; 106.en_US
dc.identifier.citedreferenceQuinn DI, Tangen CM, Hussain M, et al. Docetaxel and atrasentan compared to docetaxel and placebo for men with advanced castration resistant prostate cancer: SWOG S0421. Lancet Oncol 2013; 14: 893 – 900.en_US
dc.identifier.citedreferenceXu T, Lu B, Tai YC, et al. A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. Cancer Res 2010; 70: 6420 – 6.en_US
dc.identifier.citedreferenceLin HK, Zheng S, Williams AJ, et al. Portable filter‐based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 2010; 16: OF1 – 8.en_US
dc.identifier.citedreferenceZheng S, Lin H, Liu JQ, et al. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A 2007; 1162: 154 – 61.en_US
dc.identifier.citedreferenceTatsumoto N, Hiyama E, Murakami Y, et al. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer. Clin Cancer Res 2000; 6: 2696 – 701.en_US
dc.identifier.citedreferenceClark GM, Osborne CK, Levitt D, et al. Telomerase activity and survival of patients with node positive breast cancer. J Natl Cancer Inst 1997; 89: 1874 – 81.en_US
dc.identifier.citedreferenceSanchini MA, Gunelli R, Nanni O, et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 2005; 294: 2052 – 6.en_US
dc.identifier.citedreferenceMeeker AK. Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. Urol Oncol 2006; 24: 122 – 30.en_US
dc.identifier.citedreferenceShay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787 – 91.en_US
dc.identifier.citedreferencede Lange T, Lundblad V, eds. Telomeres, 2nd edn. New York: Cold Spring Harbor Laboratory Press, 2005.en_US
dc.identifier.citedreferenceJiang Y, Palma JF, Agus DB, et al. Detection of androgen receptor mutations in circulating tumor cells in castration‐resistant prostate cancer. Clin Chem 2010; 56: 1492 – 95.en_US
dc.identifier.citedreferenceDanila DC, Anand A, Sung CC, et al. TMPRSS2‐ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration‐resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 2011; 60: 897 – 904.en_US
dc.identifier.citedreferenceGoldkorn A, Ely B, Quinn DI, et al. Circulating tumor cell (CTC) counts are prognostic of overall survival (OS) in SWOG S0421‐docetaxel with or without atrasentan for metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2014; 32: 1136 – 42.en_US
dc.identifier.citedreferenceScher HI, Heller G, Molina A, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration‐resistant prostate cancer (mCRPC): planned final analysis (FA) of COU‐AA‐301, a randomized double‐blind, placebo‐controlled phase III study of abiraterone acetate (AA) plus low‐dose prednisone (P) post docetaxel. J Clin Oncol 2011; 29 ( Suppl ): LBA4517.en_US
dc.identifier.citedreferenceScher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration‐resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009; 10: 233 – 39.en_US
dc.identifier.citedreferencede Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration‐resistant prostate cancer. Clin Cancer Res 2008; 14: 6302 – 9. Erratum in: Clin Cancer Res 2009;15:1506.en_US
dc.identifier.citedreferenceGoodman OB, Jr, Symanowski JT, Loudyi A, et al. Circulating tumor cells as a predictive biomarker in patients with hormone‐sensitive prostate cancer. Clin Genitourin Cancer 2011; 9: 31 – 38.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ijc29212.pdf
Size:
327.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.